ArticleLeukemia2020
Reply to "CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report" Analysis of six hematological centers in Lombardy : On behalf of CLL commission of Lombardy Hematology Network (REL).
Article in Leukemia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- The Relationship between the Clinical Course of SARS-CoV-2 Infections and Expression of Bruton's Tyrosine Kinase.Infectious disorders drug targets · 2025Article
- Anticancer Therapy and Mortality of Adult Patients with Hematologic Malignancy and COVID-19: A Systematic Review and Meta-Analysis.Life (Basel, Switzerland) · 2023Review
- The Possible Role of Bruton Tyrosine Kinase Inhibitors in the Treatment of COVID-19: A Review.Current therapeutic research, clinical and experimental · 2022Review
- Management of patients with chronic lymphocytic leukemia during the SARS-CoV-2 pandemic.Oncology letters · 2021Review
- Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib.Cancers · 2021Article
- Venetoclax-Rituximab Treatment of Relapsed/Refractory CLL During the COVID-19 Pandemic: A Real-Life Experience in Selected Central-Southern Italian Regions.Mediterranean journal of hematology and infectious diseases · 2021Article
- Immune Dysfunction in Patients with Chronic Lymphocytic Leukemia and Challenges during COVID-19 Pandemic.Acta haematologica · 2021Review
- COVID-19-Induced Hyperleucocytosis in Chronic Lymphocytic Leukaemia.European journal of case reports in internal medicine · 2021Article
- Article
Corrections and comments
- Comment on
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.